Sutcliffe, Paul A., Hummel, S., Simpson, E. L. (Emma L.), Young, T. (Tracey), Rees, A. (Angie), Wilkinson, A. (Anna), Hamdy, Freddie C., Clarke, Noel W. and Staffurth, J.. (2009) Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer : a systematic review. Health Technology Assessment, Vol.13 (No.5). pp. 1-260. ISSN 1366-5278

Preview	Text WRAP_Sutcliffe_Use_classical_novel.pdf - Published Version Download (1160Kb) | Preview
Preview	Text (Coversheet) WRAP_coversheet_Sutcliffe_Use_classical_novel.pdf - Supplemental Material Download (50Kb) | Preview

Abstract

Objectives: To provide an evidence-based perspective on the prognostic value of novel markers in localised prostate cancer and to identify the best prognostic model including the three classical markers and investigate whether models incorporating novel markers are better. Data sources: Eight electronic bibliographic databases were searched during March–April 2007. The reference lists of relevant articles were checked and various health services research-related resources consulted via the internet. The search was restricted to publications from 1970 onwards in the English language. Methods: Selected studies were assessed, data extracted using a standard template, and quality assessed using an adaptation of published criteria. Because of the heterogeneity regarding populations, outcomes and study type, meta-analyses were not undertaken and the results are presented in tabulated format with a narrative synthesis of the results. Results: In total 30 papers met the inclusion criteria, of which 28 reported on prognostic novel markers and five on prognostic models. A total of 21 novel markers were identified from the 28 novel marker studies. There was considerable variability in the results reported, the quality of the studies was generally poor and there was a shortage of studies in some categories. The marker with the strongest evidence for its prognostic significance was prostate-specific antigen (PSA) velocity (or doubling time). There was a particularly strong association between PSA velocity and prostate cancer death in both clinical and pathological models. In the clinical model the hazard ratio for death from prostate cancer was 9.8 (95% CI 2.8–34.3, pÊ<Ê0.001) in men with an annual PSA velocity of more than 2Êng/ml versus an annual PSA velocity of 2Êng/ml or less; similarly, the hazard ratio was 12.8 (95% CI 3.7–43.7, pÊ<Ê0.001) in the pathological model. The quality of the prognostic model studies was adequate and overall better than the quality of the prognostic marker studies. Two issues were poorly dealt with in most or all of the prognostic model studies: inclusion of established markers and consideration of the possible biases from study attrition. Given the heterogeneity of the models, they cannot be considered comparable. Only two models did not include a novel marker, and one of these included several demographic and co-morbidity variables to predict all-cause mortality. Only two models reported a measure of model performance, the C-statistic, and for neither was it calculated in an external data set. It was not possible to assess whether the models that included novel markers performed better than those without. Conclusions: This review highlighted the poor quality and heterogeneity of studies, which render much of the results inconclusive. It also pinpointed the small proportion of models reported in the literature that are based on patient cohorts with a mean or median follow-up of at least 5 years, thus making long-term predictions unreliable. PSA velocity, however, stood out in terms of the strength of the evidence supporting its prognostic value and the relatively high hazard ratios. There is great interest in PSA velocity as a monitoring tool for active surveillance but there is as yet no consensus on how it should be used and, in particular, what threshold should indicate the need for radical treatment.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Biochemical markers, Prostate -- Cancer -- Risk factors, Prostate -- Cancer -- Prognosis
Journal or Publication Title:	Health Technology Assessment
Publisher:	NIHR Health Technology Assessment programme
ISSN:	1366-5278
Date:	January 2009
Volume:	Vol.13
Number:	No.5
Page Range:	pp. 1-260
Identification Number:	10.3310/hta13050
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
References:	1. Zhang C, Li HR, Fan JB, Wang-Rodriguez J, Downs T, Fu XD, et al. Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics 2006;7:202. 2. Gronau E, Goppelt M, Harzmann R, Weckermann D. Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma. Onkologie 2005;28:361–6. 3. Harris R. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;137:917–29. 4. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943–53. 5. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388–1413. 6. Parkin DM, Whelan J, Ferlay L, Teppo L, Thomas DB. Cancer incidence in five continents. Volume VIII. IARC Scientific Publication No. 155. Lyon: IARC; 2002. 7. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30. 8. Office for National Statistics. Registrations of cancer diagnosed in 1993–1996, England and Wales. Health Stat Quart 1999;4:59–70. 9. Cancer Research UK. UK prostate cancer mortality statistics. URL: http://info.cancerresearchuk.org/ cancerstats/types/prostate/mortality/2007. Accessed 11 October 2007. 10. Srigley JR, Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, et al. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl 2005;216:8– 19. 11. Bailey JA. Concise dictionary of medical-legal terms. New York: Parthanon Publishing Group; 1998. 12. Chamberlain J, Melia J, Moss S, Brown J. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1997;1:(3). 13. Ilic D, O’Connor D, Green S, Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control 2007;18:279–85. 14. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol 1995;154:2144–8. 15. Prostate Cancer Speciality Working Group. Clinical Information Network guidelines on the management of prostate cancer. Springer-Verlag, London: British Association of Urological Surgeons and Royal College of Radiologists; 1999. 16. Hummel S, Paisley S, Morgan A, Currie E. Clincial and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess 2003;7(33). 17. NICE. Improving outcomes in urological cancers. 2002. URL: http://guidance.nice.org.uk/csguc/guidance/ pdf/English. 18. Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, et al. New nomenclature for the human tissue kallikrein gene family. Clin Chem 2000;46:1855–8. 19. Ablin RJ, Bronson RT, Soanes WA. Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol 1970;104:1329–39. 20. Hara M, Koyanagi Y, Inoue T. Some physiochemical characteristics of seminoprotein, an antigenic component specific for human seminal plasma. Nippon Hoigaku Zasshi 1971;25:322–4. 21. Li TS, Beling CG. Isolation and characterisation of two specific antigens of human seminal plasma. Fertil Steril 1973;24:134–44. 22. Sensabaugh GF, Crim D. Isolation and characterisation of a semen-specific protein from human seminal plasma: a potential new market for semen idenitification. J Forensic Sci 1978;23:106–15. 23. Wang MC, Valenzuela LA, Murphy GP. Purification of a human prostate specific antigen. Invest Urol (Berlin) 1979;17:159–63. 24. Hughes C, Murphy A, Martin C, Sheils O, O’Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005;58:673–84. 25. Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process for continuous improvement of the TNM classification. Cancer 2003;100:1–5. 26. Balch C, Soong CM, Gershenwald JE. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622–34. 27. Sobin LH, Wittekind CL. TNM classification of malignant tumors. 6th edn. New York: John Wiley; 2002. 28. Brierley, J. The evolving TNM cancer staging system: an essential component of cancer care. CMAJ 2006;170. 29. Jewett HJ. The present status of radical prostetectomy for stages A and B prostatic cancer. Urol Clin N Am 1975;2:105–24. 30. Jackson AS, Parker CC, Norman AR, Padhani AR, Huddart RA, Horwich A, et al. Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. Clin Oncol 2005;17:167–71. 31. Albertsen PC. PSA and the conservative treatment of early prostate cancer. Arch Ital Urol Androl 2006;78:152–3. 32. Epstein JI. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol 216;39:34–63. 33. Epstein JI, Pizov G, Walsh PC, Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582–93. 34. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818–24. 35. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821–5. 36. Epstein JI. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286–92. 37. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, et al. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol 2005;216(Suppl):64–81. 38. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981–90. 39. Grizzle W. Biomarkers in prostate cancer. AACR Education Book 2005. Stanford, CA: American Association for Cancer Research; 2005. pp. 196– 204. 40. Barranco C. Preoperative PSA kinetics predict prostate cancer outcomes. Nat Clin Pract Urol 2006;3:64–65. 41. Polascik TJ, Pearson JD, Partin AW. Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostatespecific antigen. Semin Urol Oncol 1998;16:160–71. 42. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445–51. 43. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110–14. 44. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 1992;70:161–8. 45. Hammond ME, Fitzgibbons PL, Compton CC, Grignon DJ, Page DL, Fielding LP, et al. College of American Pathologists Conference XXXV: solid tumor prognostic factors – which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch Pathol Lab Med 2000;124:958–65. 46. Ross JS, Sheehan CE, Fisher HA, Kauffman RA, Dolen EM, Kallakury BV, et al. Prognostic markers in prostate cancer. Exp Rev Mol Diagn 2002;2:129– 42. 47. Ross JS, Sheehan CE, Dolen EM, Kallakury BV, Ross JS, Sheehan CE, et al. Morphologic and molecular prognostic markers in prostate cancer. Adv Anat Pathol 2002;9:115–28. 48. Ergun A, Lawrence CA, Kohanski A, Brennan TA, Collins JJ. A network biology approach to prostate cancer. Mol Syst Biol 2007;3:82. 49. Draisma, G. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–78. 50. McShane LM, Altman DA, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180–4. 51. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 2003;88:1191–8. 52. Altman D, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998;52:289–303. 53. von Eschenbach AC, Brawer M, di Sant’ Agnese PA, Humphrey P, Mahran HE, Murphy G, et al. Exploration of new pathologic factors in prostate cancer in terms of potential for pronostic significance and future applications. Cancer 1996;78:372–5. 54. Marchevsky AM, Wick MR. Evidence-based medicine, medical decision analysis, and pathology. Hum Pathol 2004;35:1179–88. 55. Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999;17:222–72. 56. Chun FK, Karakiewicz PI, Briganti A, Gallina A, Kattan MW, Montorsi F, et al. Prostate cancer nomograms: an update. Eur Urol 2006;50:914–26. 57. Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanagh W, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393–9. 58. Sargent DJ. Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer 2001;91:1636–42. 59. Abbod MF, Catto JW, Linkens DA, Hamdy FC. Application of artificial intelligence to the management of urological cancer. J Urol 2007;178:1150–6. 60. Babaian RJ, Zhang Z. Computer-assisted diagnostics: application to prostate cancer. Mol Urol 2001;5:175–80. 61. Ross PL, Scardino PT, Kattan MW, Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001;165:1562–8. 62. Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21:3573–9. 63. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr, Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715–17. 64. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr, Dotan ZA, DiBlasio CJ, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23:7005–12. 65. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499–1507. 66. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18:3352–9. 67. Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 2003;21:4568–71. 68. Kattan MW. A nomogram which predicts 7-year metastasis-free survival following 3D conformal radiation therapy. J Urol 2002;167:355. 69. Kattan MW. A nomogram which uses postoperative factors to predict PSA progression after radical prostatectomy for clinically localized prostate cancer. J Urol 1998;159:182. 70. Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT, et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005;104:290–8. 71. Memorial Sloan-Kettering Center prostate cancer nomograms. URL: http://info.cancerresearchuk.org/ cancerstats/types/prostate/mortality/2007. 72. Hoffman RM, Stone SN, Hunt WC, Key CR, Gilliland FD. Effects of misattribution in assigning cause of death on prostate cancer mortality rates. Ann Epidemiol 2003;13:450–4. 73. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer. II. Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999;91:1025–32. 74. Roach M, III, Hanks G, Thames H, Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG–ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74. 75. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540–5. 76. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001;165:1146– 51. 77. Mills N, Metcalfe C, Ronsmans C, Davis M, Lane JA, Sterne JAC, et al. A comparison of sociodemographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). Contemp Clin Trials 2006;27:413–19. 78. Stattin P, Damber JE, Karlberg L, Nordgren H, Bergh A, Stattin P, et al. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res 1996;24:257–64. 79. van Gils MP, Stenman UH, Schalken JA, Schroder FH, Luider TM, Lilja H, et al. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol 2005;48:1031–41. 80. Bubendorf L. High-throughput microarray technologies: from genomics to clinics. Eur Urol 2001;40:231–8. 81. Bok RA, Small EJ. Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2002;2:918–26. 82. Falcone A, Antonuzzo A, Danesi R, Allegrini G, Monica L, Pfanner E, et al. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 1999;86:470–6. 83. Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, et al. Identification of genetic markers for prostatic cancer progression. Lab Invest 2000;80:931–42. 84. Abate-Shen C, Shen M. Molecular genetics of prostate cancer. Genes Dev 2000;14:2410–34. 85. Roemeling S, Schroder FH, Bangma CH. Guideline and study for the expectant management of localized prostate cancer with curative intent. Study protocol, version 3.3e. Rotterdam: Department of Urology, Erasmus MC, University Medical Center; 2006. 86. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. and Scandinavian Prostate Cancer Group. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977–84. 87. Johansson J, Andren O, Andersson S, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713–9. 88. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Johan Norlen B, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790–6. 89. D’Amico AV, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, et al. Changing prostatespecific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 2002;54:436–41. 90. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Fujian S. Methods for meta-analysis in medical research. Chichester: John Willey & Sons; 2000. 91. Egger M, Davey Smith G, Altman DG. Systematic reviews in health care: meta-analsysis in context, 2nd edn. London: BMJ Books; 2001. 92. Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, et al. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess 2006;10(34). 93. Roach M, III, Hanks G, Thames H, Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: receommendations of the RTOG–ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2007;66:1274–5. 94. Critz FA, Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 2004;172:2232–8. 95. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003;170:1872–6. 96. Altman D. Systematic reviews in health care: systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224–8. 97. Counsell C, Dennis M. Systematic review of prognostic models in patients with acute stroke. Cerebrovasc Dis 2001;12:159–70. 98. Meijer R, Ihnenfeldt DS, de Groot IJM, van Limbeek J, Vermeulen M, de Haan RJ. Prognostic factors for ambulation and activities of daily living in the subacute phase after stroke. A systematic review of the literature. Clin Rehabil 2003;17:119– 29. 99. Jacob M, Lewsey JD, Sharpin C, Gimson A, Rela M, van der Meulen JHP. Systematic review and validation of prognostic models in liver transplantation. Liver Transpl 2005;11:814–25. 100. Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, et al. A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing’s sarcoma and neuroblastoma. Health Technol Assess 2003;7(5). 101. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, et al. P. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004;91:2018–25. 102. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427–37. 103. Stemey TA, Caldwell MC, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297–1301. 104. Parker CC, Gospodarowicz M, Warde P. Does age influence the behaviour of localized prostate cancer? BJU Int 2001;87:629–37. 105. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119–25. 106. Lieber MM, Murtaugh P, Farrow GM, Myers RP, Blute M. DNA ploidy and surgically treated prostate cancer: important independent association with prognosis for patients with prostate carcinoma treated by radical prostatectomy. Cancer 1995;75:1935–43. 107. Vollmer RT, Humphrey PA, Vollmer RT, Humphrey PA. The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. Am J Clin Pathol 2001;116:864–70. 108. Horvath LG, Henshall SM, Lee CS, Kench JG, Golovsky D, Brenner PC, et al. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer 2005;113:415–22. 109. Anscher MS, Prosnitz LR. Multivariate analysis of factors predicting local relapse after radical prostatectomy – possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1991;21:941–7. 110. Han M, Piantadosi S, Zahurak ML, Sokoll LJ, Chan DW, Epstein JI, et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 2001;57:707–11. 111. Perez CA, Garcia D, Simpson JR, Zivnuska F, Lockett MA. Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate. Radiother Oncol 1989;16:1–21. 112. Roach M, III, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, et al. Long-term survival after radiotherapy alone: radiation therapy oncology group prostate cancer trials. J Urol 1999;161:864–8. 113. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 1993;72:1709–25. 114. Nam RK, Elhaji Y, Krahn MD, Hakimi J, Ho M, Chu W, et al. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000;164:567– 72. 115. Powell IJ, Land SJ, Dey J, Heilbrun LK, Hughes MB, Sakr W, et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer 2005;103:528–37. 116. Merseburger AS. Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. Urology 2001;58:729–34. 117. Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 1987;60:1489–99. 118. Powell IJ, Zhou J, Sun Y, Sakr WA, Patel NP, Heilbrun LK, et al. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol 2004;172:1848– 52. 119. Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol 2006;175:952–7. 120. Williams H, Powell IJ, Land SJ, Sakr WA, Hughes MR, Patel NP, et al. Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy. Prostate 2004;61:267–75. 121. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. J Urol 2002;168:509–13. 122. Gonzalgo ML, Bastian PJ, Mangold LA, Trock BJ, Epstein JI, Walsh PC, et al. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology 2006;67:115–19. 123. Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 2006;175:547–51. 124. Vis AN, Roemeling S, Kranse R, Schroder FH, van der Kwast TH. Should we replace the Gleason score with the amount of high-grade prostate cancer? Eur Urol 2007;51:931–9. 125. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003;55:20–9. 126. Antunes AA, Srougi M, Dall’Oglio MF, Crippa A, Campagnari JC, Leite KR. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy. BJU Int 2005;96:1258– 63. 127. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173:1562–6. 128. Selek U, Lee A, Levy L, Kuban DA. Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;57:963–7. 129. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125–35. 130. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005;174:2191–6. 131. Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, et al. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 2005;11:5863–8. 132. Salomon L, Levrel O, Anastasiadis AG, Irani J, de la Taille A, Saint F, et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 2003;43:39–44. 133. Morita N, Uemura H, Tsumatani K, Cho M, Hirao Y, Okajima E, et al. E-cadherin and alpha-, betaand gamma-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer 1999;79:1879–83. 134. Lowe FC, Trauzzi SJ. Prostatic acid phoshatase in 1993. Its limited clinical utility. Urol Clin N Am 1993;20:589–95. 135. Giovannucci E. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94:3320–3. 136. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164:101–5. 137. Montgomery BT, Nativ O, Blute ML, Farrow GM, Myers RP, Zincke H, et al. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg 1990;125:327–31. 138. Winkler HZ, Rainwater LM, Myers RP, Farrow GM, Therneau TM, Zincke H, et al. Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 1988;63:103–12. 139. So MJ, Cheville JC, Katzmann JA, Riehle DL, Lohse CM, Pankratz VS, et al. Factors that influence the measurement of prostate cancer DNA ploidy and proliferation in paraffin embedded tissue evaluated by flow cytometry. Mod Pathol 2001;14:906–12. 140. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517–23. 141. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol 2005;216(Suppl)34–63. 142. Anttonen A, Leppä S, Heikkilä P, Grenman R, Joensuu H. Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations. J Cancer Res Clin Oncol 2006;7:451–7. 143. Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol 2006;176:439–49. 144. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using ‘optimal’ cutpoints in the evaluation of prognositc factors. J Natl Cancer Inst 1994;86:829–35. 145. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453–73. 146. Justice AC, Covinsky KE, Berlin JA. Assessing the generalisability of prognostic information. Ann Intern Med 1999;130:515–24. 147. Vergouwe Y, Steyerberg EW, Eijkemans MJC, Habbema JDF. Validity of prognostic models: when is a model clinically useful? Semin Oncol 2002;20:96–107. 148. Braitman LE, Davidoff F. Predicting clinical states in individual patients. Ann Intern Med 1996;125:406–12. 149. Harrell FE, Lee KL, Mark DB. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–87. 150. Cowen ME, Halasyamani LK, Kattan MW. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 2006;175:99–103. 151. Graefen M. Can nomograms derived in the US be applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy. Urologe A 2003;42:685–92. 152. Dunsmuir WD, Gillett CE, Meyer LC, Young MP, Corbishley C, Eeles RA, et al. Molecular markers for predicting prostate cancer stage and survival. BJU Int 2000;86:869–78. 153. Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD. Should the Gleason grading system for prostate cancer be modified to account for highgrade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007;8:411–19. 154. Harnden P, Shelley MD, Clements H, Coles B, Tyndale-Biscoe RS, Naylor B, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer 2007;109:13–24. 155. McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 2005;97:1023–5. 156. Altman DG. Systematic reviews of studies of prognostic variables. In Egger M, Davy Smith G, Altman DG, editors, Systematic reviews of health care: meta-analysis in context. London: BMJ Books; 2001. pp. 228–47. 157. Hutchon DJR. Publishing raw data and real time statistical analysis on e-journals. Br Med J 2001;322:530. 158. Stewart LA, Palmar MKB. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993;341:418–22. 159. Kyzas PA, Loizou KT, Ioannidis JPA. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043–55. 160. Sauerbrei W, Hollander N, Riley RD, Altman DG. Evidence based assessment and application of prognostic markers: the long way from single studies to meta-analysis. Commun Stat Theor Methods 2006;35:1333–42. 161. Altman DG, Trivella M, Pezzella F, Harris AL, Pastorino U. Systematic review of multiple studies of prognosis: the feasibility of obtaining individual patient data. In Auget J-L, Balakrishna L, Mesbah N, Molenberghs, editors, Advances in statistical methods for the health sciences. Basel: Birkhauser; 2007; pp.3–18. 162. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006;25:127–41. 163. Riley RD, Ridley G, William K, Altman DG, Hayden J, de Vet HC. Prognosis research: towards evidencebased results and a Cochrane methods group. J Clin Epidemiol 2007;60:863–5. 164. Holländer N, Sauerbrei W. On statistical approaches for the multivariable analysis of prognostic factor studies. In Auget J-L, Balakrishna L, Mesbah N, Molenberghs, editors, Advances in statistical methods for the health sciences. Basel: Birkhauser; 2007; pp.19–38. 165. Simon R, Altman D. Statistical aspects of prognostic factor studies in onclology. Br J Cancer 1994;69:979–85. 166. Burton A, Altman DG. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer 2004;91:4–8. 167. Altman DG, De Stavola BL, Love SB, Stepiewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995;72:511–18. 168. Riley RD, Abrams KR, Lambert PC, Sutton AJ, Altman DG. Where next for evidence synthesis of prognostic marker studies? Improving the quality and reporting of primary studies to facilitate clinically relevant evidence-based results. In Auget J-L, Balakrishna L, Mesbah N, Molenberghs, editors, Advances in statistical methods for the health sciences. Basel: Birkhauser; 2007; pp.39–58. 169. Antunes AA, Dall’Oglio MF, Sant’Anna AC, Paranhos M, Leite KR, Srougi M. Prognostic value of the percentage of positive fragments in biopsies from patients with localized prostate cancer. Int Braz J Urol 2005;31:34–41. 170. Hedley DW. DNA flow cytometry and breast cancer. Breast Cancer Res Treat 1993;28:51–53
URI:	http://wrap.warwick.ac.uk/id/eprint/37399

Request changes to a record

Actions (login required)

View Item